{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:48:03Z","timestamp":1794044883926,"version":"4.8.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS090107"],"award-info":[{"award-number":["NS090107"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001288","name":"Parkinson's Disease Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016703","name":"Kansas Soybean Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016703","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.expneurol.2023.114522","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T10:51:55Z","timestamp":1693047115000},"page":"114522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine"],"prefix":"10.1016","volume":"369","author":[{"given":"Timothy J.","family":"Collier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Begg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Stancati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natosha M.","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhyomi C.","family":"Sellnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette M.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caryl E.","family":"Sortwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Steece-Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2023.114522_bb0005","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/BST0380493","article-title":"Synaptic dysfunction in Parkinson\u2019s disease","volume":"38","author":"Bagetta","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.expneurol.2023.114522_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113413","article-title":"Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia","volume":"333","author":"Bartlett","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0020","doi-asserted-by":"crossref","first-page":"22114","DOI":"10.1074\/jbc.M908836199","article-title":"Molecular mechanism of calcium channel block by isradipine. Role of a drug-induced inactivated channel conformation","volume":"275","author":"Berjukow","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2023.114522_bb0025","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1523\/JNEUROSCI.15-07-05372.1995","article-title":"Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism","volume":"15","author":"Borlongan","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0030","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1097\/00001756-199811160-00012","article-title":"Early assessment of motor dysfunctions aids in successful occlusion of the middle cerebral artery","volume":"9","author":"Borlongan","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2023.114522_bb0035","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0040","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nbd.2015.03.005","article-title":"Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration","volume":"77","author":"Collier","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2023.114522_bb0045","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1056\/NEJM196907312810517","article-title":"L-DOPA in parkinson\u2019s syndrome","volume":"281","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2023.114522_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nn1632","article-title":"Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models","volume":"9","author":"Day","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0055","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/ncomms6316","article-title":"Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia","volume":"5","author":"Fieblinger","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2023.114522_bb0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0074-7742(09)89003-X","article-title":"Behavioral outcome measures for the assessment of sensorimotor function in animal models of movement disorders","volume":"89","author":"Fleming","year":"2009","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbr.2004.05.024","article-title":"An intermittent, controlled-rate, slow progressive degeneration model of Parkinson\u2019s disease: antiparkinson effects of Sinemet and protective effects of methylphenidate","volume":"156","author":"Fleming","year":"2005","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2023.114522_bb0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/gt.2014.42","article-title":"Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways","volume":"21","author":"Gombash","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.expneurol.2023.114522_bb0075","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.21743","article-title":"Ten-year follow-up of Parkinson\u2019s disease patients randomized to initial therapy with ropinirole or levodopa","volume":"22","author":"Hauser","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0080","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 study): interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2023.114522_bb0085","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/35104061","article-title":"Dendritic spines: structure, dynamics and regulation","volume":"2","author":"Hering","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0090","doi-asserted-by":"crossref","first-page":"8987","DOI":"10.1523\/JNEUROSCI.20-24-08987.2000","article-title":"D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade","volume":"20","author":"Hernandez-Lopez","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of L-DOPA-induced dyskinesia in Parkinson\u2019s disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2023.114522_bb0100","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(89)91686-7","article-title":"Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age","volume":"503","author":"Ingham","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2023.114522_bb0105","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1523\/JNEUROSCI.18-12-04732.1998","article-title":"Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway","volume":"18","author":"Ingham","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/neur.1995.0016","article-title":"6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death","volume":"4","author":"Jeon","year":"1995","journal-title":"Neurodegen"},{"key":"10.1016\/j.expneurol.2023.114522_bb0115","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/ncomms2149","article-title":"CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease","volume":"3","author":"Kang","year":"2012","journal-title":"Nature Comm."},{"key":"10.1016\/j.expneurol.2023.114522_bb0120","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","article-title":"Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics","volume":"21","author":"Kang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.expneurol.2023.114522_bb0125","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1021\/jm4005048","article-title":"Structure-activity relationship of N,N\u2019-disubstituted pyrimidinetriones as Ca(V)1.3 calcium channel-selective antagonists for Parkinson\u2019s disease","volume":"56","author":"Kang","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.expneurol.2023.114522_bb0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.nbd.2004.07.005","article-title":"Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia","volume":"17","author":"Konradi","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2023.114522_bb0135","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbr.2010.04.034","article-title":"Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat","volume":"213","author":"Lane","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2023.114522_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jneumeth.2012.12.001","article-title":"Advances in thin tissue Golgi-cox impregnation: fast, reliable methods for multi-assay analyses in rodent and non-human primate brain","volume":"213","author":"Levine","year":"2013","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2023.114522_bb0145","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole study group","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2023.114522_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pharmtox-010818-021214","article-title":"The potential of L-type calcium channels as a drug target for neuroprotective therapy in Parkinson\u2019s disease","volume":"59","author":"Liss","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M20-1023","article-title":"A clinical trial of Isradipine: what went wrong?","volume":"172","author":"Maiti","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.expneurol.2023.114522_bb0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0014-4886(73)90091-5","article-title":"Demonstration of the nigrostriatal projection by silver staining after nigral injections of 6-hydroxydopamine","volume":"40","author":"Maler","year":"1973","journal-title":"Exp. Neurol."},{"issue":"471\u2013482","key":"10.1016\/j.expneurol.2023.114522_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cmdc.201290007","article-title":"Investigation of D(2) receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling","volume":"7","author":"Malo","year":"2012","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.expneurol.2023.114522_bb0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nbd.2005.07.002","article-title":"Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats","volume":"21","author":"Maries","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2023.114522_bb0175","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0165-0173(01)00147-3","article-title":"The role of synaptic morphology in neural plasticity: structural interactions underlying synaptic power","volume":"38","author":"Marrone","year":"2002","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.expneurol.2023.114522_bb0180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuroscience.2010.12.057","article-title":"Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease","volume":"177","author":"Martella","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2023.114522_bb0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0006-8993(88)90124-2","article-title":"Atrophy of medium spiny I striatal dendrites in advanced Parkinson\u2019s disease","volume":"455","author":"McNeill","year":"1988","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2023.114522_bb0190","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00002826-199510000-00004","article-title":"Effects of calcium antagonists on the dopamine system","volume":"18","author":"Mena","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0195","article-title":"BDNF in the aged brain: translational implications for Parkinson\u2019s disease","volume":"2","author":"Mercado","year":"2017","journal-title":"Austin. Neurol. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0200","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp.57.9.1034","article-title":"A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson\u2019s disease: a five year follow up","volume":"57","author":"Montastruc","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2023.114522_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00008877-199308000-00041","article-title":"\u201cpriming\u201d to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message","volume":"4","author":"Morelli","year":"1993","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.expneurol.2013.01.024","article-title":"Modelling of dyskinesia in animal models of Parkinson\u2019s disease","volume":"256","author":"Morin","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0215","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mds.25826","article-title":"Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model","volume":"29","author":"Nishijima","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson\u2019s disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0225","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40263-018-0552-2","article-title":"Amantadine extended-release (GOCOVRI): a review in levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Paik","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2023.114522_bb0230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/M19-2534","article-title":"Isradipine versus placebo in early Parkinson disease: a randomized trial","volume":"172","author":"Parkinson Study Group, S.-P.D.I.I.I.I","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.expneurol.2023.114522_bb0235","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1172\/JCI59426","article-title":"PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking","volume":"122","author":"Porras","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2023.114522_bb0240","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.37.5.826","article-title":"Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up","volume":"37","author":"Rinne","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2023.114522_bb0245","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.0000000000000068","article-title":"Amantadine's role in the treatment of levodopa-induced dyskinesia","volume":"82","author":"Rodnitzky","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2023.114522_bb0250","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.nurx.2006.08.001","article-title":"Behavioral tests for preclinical intervention assessment","volume":"3","author":"Schallert","year":"2006","journal-title":"NeuroRx: J. Am. Soc. Exper. NeuroTherap."},{"key":"10.1016\/j.expneurol.2023.114522_bb0255","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biopsych.2008.09.008","article-title":"Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"65","author":"Schuster","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2023.114522_bb0260","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/mp.2016.200","article-title":"Endocytosis following dopamine D2 receptor activation is critical for neuronal activity and dendritic spine formation via Rabex-5\/PDGFRbeta signaling in striatopallidal medium spiny neurons","volume":"22","author":"Shioda","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.expneurol.2023.114522_bb0265","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.nbd.2008.06.018","article-title":"The synaptic impact of the host immune response in a parkinsonian allograft rat model: influence on graft-derived aberrant behaviors","volume":"32","author":"Soderstrom","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2023.114522_bb0270","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1460-9568.2010.07077.x","article-title":"Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats","volume":"31","author":"Soderstrom","year":"2010","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0275","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/mds.10588","article-title":"Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats","volume":"18","author":"Steece-Collier","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cne.22037","article-title":"Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats","volume":"515","author":"Steece-Collier","year":"2009","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0285","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/mds.27695","article-title":"Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia","volume":"34","author":"Steece-Collier","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0290","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.biopsych.2013.05.006","article-title":"L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice","volume":"75","author":"Suarez","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2023.114522_bb0295","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1093\/cercor\/bhw263","article-title":"L-DOPA oppositely regulates synaptic strength and spine morphology in D1 and D2 striatal projection neurons in dyskinesia","volume":"26","author":"Suarez","year":"2016","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.expneurol.2023.114522_bb0300","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.expneurol.2017.08.001","article-title":"Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease","volume":"298","author":"Surmeier","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0305","series-title":"Isradipine Plasma Pharmacokinetics and Exposure-Response in Early Parkinson\u2019s Disease","author":"Venuto","year":"2021"},{"key":"10.1016\/j.expneurol.2023.114522_bb0310","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.expneurol.2008.09.025","article-title":"Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys","volume":"215","author":"Villalba","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2023.114522_bb0315","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.22890","article-title":"Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson\u2019s disease","volume":"25","author":"Watts","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2023.114522_bb0320","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1523\/JNEUROSCI.21-16-05944.2001","article-title":"Neuronal ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines","volume":"21","author":"Xu","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0325","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2014.12.010","article-title":"Regulation of dopamine D2 receptor-mediated extracellular signal-regulated kinase signaling and spine formation by GABAA receptors in hippocampal neurons","volume":"586","author":"Yoon","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2023.114522_bb0330","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","article-title":"Aberrant restoration of spines and their synapses in L-DOPA-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses","volume":"33","author":"Zhang","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2023.114522_bb0335","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0006-3495(95)80305-X","article-title":"Kinetic analysis of barium currents in chick cochlear hair cells","volume":"68","author":"Zidanic","year":"1995","journal-title":"Biophys. J."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488623002078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488623002078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:56:34Z","timestamp":1762149394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488623002078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":67,"alternative-id":["S0014488623002078"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2023.114522","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2023.114522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114522"}}